Galmed Pharmaceuticals financials at a glance

+ Portfolio

The revenue of Galmed Pharmaceuticals is reported as 0 billion Dollars in the fiscal year 2023. The earnings were 0 Dollars per share in 2023, which was 2.22 higher than 2020. And about -2.0E-5 billion Dollars are reported as free cash flow in the financials of Galmed Pharmaceuticals 2023. No dividends were paid to the shareholders of the Galmed Pharmaceuticals stock NasdaqCM:GLMD in the financial year 2023.

Forecast

Financials

Year	Year	TTM	2021	2020	2019	2018	2017	2016	2015	2014
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M	$2.04M	$1.09M	$0.47M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-2.66	$-19.80	$-20.25	$-14.55	$-8.10	$-14.70	$-22.35	$-14.40	$-13.20
Div.	Dividends	N/A	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	1.67M	1.67M	1.41M	1.41M	0.96M	0.81M	0.74M	0.74M
OCF	Operating Cash Flow	N/A	$0.00M	$-26.29M	$-14.94M	$-9.02M	$-12.07M	$-12.13M	$0.00M	$0.00M
FCF	Free Cash Flow	N/A	$0.00M	$-26.33M	$-14.95M	$-11.62M	$-12.08M	$-12.15M	$0.00M	$0.00M
FCFS	Free Cash Flow Per Share	$-3.27	$-1.34	$-1.24	$-0.71	$-0.50	$-0.97	$-1.07	$-0.78	$-0.97

Galmed Pharmaceuticals financials at a glance

Financials

Discover